A phase i and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 3, 2014, Pages 223-230

  Foran, James ^a   Ravandi, Farhad ^b   Wierda, William ^b   Garcia Manero, Guillermo ^b   Verstovsek, Srdan ^b   Kadia, Tapan ^b   Burger, Jan ^b   Yule, Murray ^c   Langford, Gillian ^c   Lyons, John ^c   Ayrton, John ^c   Lock, Victoria ^c   Borthakur, Gautham ^b   Cortes, Jorge ^b   Kantarjian, Hagop ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Blood cancer; Clinical; Dose escalation; Response; Tolerability

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ABELSON KINASE; AURORA B KINASE; DASATINIB; DIURETIC AGENT; IMATINIB; JANUS KINASE 2; 1-CYCLOPROPYL-3-(3-(5-MORPHOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL)UREA; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; UREA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASSISTED VENTILATION; BLAST CELL; BONE MARROW CELL; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOPULMONARY ARREST; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; HYPERTENSION; IC 50; IMMUNE DEFICIENCY; INFECTION; INFECTIOUS COMPLICATION; KIDNEY DISEASE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELOFIBROSIS; MYELOFIBROSIS WITH MYELOID METAPLASIA; MYELOID METAPLASIA; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; RESPIRATORY FAILURE; SEPSIS; STOMATITIS; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR LYSIS SYNDROME; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; LEUKEMIA; MIDDLE AGED; PATHOLOGY; PRIMARY MYELOFIBROSIS; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; RECURRENCE; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84900000570     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.11.001     Document Type: Article

References (15)

1. M. Carmena, and W.C. Earnshaw The cellular geography of Aurora Kinases Nat Rev Mol Cell Biol 4 2003 842 854
2. S. Sen, H. Zhou, and R.A. White A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines Oncogene 14 1997 2195 2200
3. J.R. Bischoff, L. Anderson, and Y. Zhu et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers EMBO J 17 1998 3052 3065
4. H. Katayama, T. Ota, and F. Jisaki et al. Mitotic kinase expression and colorectal cancer progression J Natl Cancer Inst 91 1999 1160 1162
5. K. Kamada, Y. Yamada, and T. Hirao et al. Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis Oncol Rep 12 2004 593 599
6. S.S. Farag The potential role of Aurora kinase inhibitors in haematological malignancies Br J Haematol 155 2011 561 579 http://doi:10.1111/j. 1365-2141.2011.08898.x
7. A.S. Moore, J. Blagg, and S. Linardopoulos et al. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias Leukemia 24 2010 671 678 http://doi:10.1038/leu. 2010.15
8. S.A. Hartsink-Segers, C.M. Zwaan, and C. Exalto et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target Leukaemia 27 2013 560 568 http://doi:10.1038/leu.2012.256
9. B. Löwenberg, P. Muus, and G. Ossenkoppele et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia Blood 118 2011 6030 6036 http://doi:10.1182/blood-2011-07-366930
10. T.A. Carter, L.M. Wodicka, and N.P. Shah et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases PNAS 102 2005 11011 11016 http://doi:10.1073/pnas.0504952102
11. Goodall J, Squires MS, Lock V, et al. AT9283, a multi-targeted kinase inhibitor, has potent activity in AML cell lines and patient samples. Poster 1613, American Society of Hematology (ASH) annual meeting, 2008.
12. G. Barosi, V. Poletto, and M. Massa et al. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis PLoS One 2013 March 26 http://doi:10.1371/journal.pone.0059791
13. H.G. Hubbeling, D.M. Frank, and E.O. Hexner Myelofibrosis 2012: it's complicated Ther Adv Hematol 3 2012 131 146 http://doi:10.1177/2040620712437754
14. A. Quintás-Cardama, and S. Verstovsek Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance Clin Cancer Res 19 2013 1933 1940 http://doi:10.1158/1078-0432.CCR-12-0284
15. T.W. Failes, G. Mitic, and H. Abdel-Halim et al. Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells PLoS One 2012 Feb 16 http://doi:10.1371/journal.pone.0030734